rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alpha Teknova, Inc.

TKNO · Nasdaq

Health CareDiagnostics & LabsLeading

TKNO stood above a rising 150-day average in 17 of the last 52 weekly readings, including each of the last 17 weeks. It is 25.9% above that average now. Diagnostics & Labs: 50% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
17 in a row
Industry in uptrend
50% +2 in 4 wk
Insider buys, 12 months
$287K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
79 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

20 Apr – 19 Oct
18%36%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$275KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Matthew LowellChief Financial Officerbought40,000at $2.196 Mar 2026filed 9 Mar 2026
Stephen GunstreamPresident and CEObought26,000at $2.156 Mar 2026filed 9 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders79+2 on the quarter
New · exited13 · 10
Reported value$51.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20261,661,395$9.4M+592,233+55.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,614,045$9.2M+1,172,166+265.3%
Roubaix Capital, LLCreduced · filed 10 Aug 20261,579,404$9.0M-302,951−16.1%
BlackRock, Inc.added · filed 7 Aug 2026879,786$5.0M+163,012+22.7%
UBS Group AGadded · filed 13 Aug 2026631,967$3.6M+306,804+94.4%
Conestoga Capital Advisors, LLCreduced · filed 24 Jul 2026314,554$1.8M-2,530−0.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026311,818$1.8M+3,945+1.3%
BANK OF AMERICA CORPadded · filed 14 Aug 2026255,760$1.5M+27,474+12.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026172,017$977K+53,578+45.2%
STATE STREET CORPadded · filed 7 Aug 2026164,885$937K+9,796+6.3%
31 Mar 2023 – 30 Jun 2026
275277Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Martha J. Demski Company insiderDirector · last 14 Jul 20260 · 1
Alexander Vos Company insiderDirector · last 1 Jun 20260 · 0
Brett Robertson Company insiderDirector · last 1 Jun 20260 · 0
Matthew Lowell Company insiderChief Financial Officer · last 6 Mar 20265 · 0
Stephen Gunstream Company insiderPresident and CEO · last 6 Mar 20267 · 0
Damon Terrill Company insiderGeneral Counsel and CCO · last 15 Feb 20261 · 0
Telegraph Hill Partners Iv, L.p. Company insider10% owner · last 12 Jul 20241 · 0
Ken Gelhaus Company insiderChief Commercial Officer · last 30 Nov 20233 · 0
Robert McNamara Company insiderDirector · last 30 Nov 20230 · 0
Lisa Hood Company insiderChief People Officer · last 14 Nov 20233 · 3
J. Matthew Mackowski Company insiderDirector · last 19 Sep 20232 · 0
Telegraph Hill Partners Management Company, Llc Company insider10% owner · last 19 Sep 20231 · 0

Same industry

CDNA CareDxLeading+90%
NTRA NateraLeading+47%
XGN ExagenLeading+42%
PSNL PersonalisLeading+36%
BDSX BiodesixLeading+17%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202533.2%
Operating profit marginFY 2025 · to 31 Dec 2025-41.9%
Free cash flow marginFY 2025 · to 31 Dec 2025-24.2%
Return on capital employedFY 2025 · to 31 Dec 2025-17.7%
Debt to equityFY 2025 · to 31 Dec 20250.19×
Interest coverFY 2025 · to 31 Dec 202523.91×
Research spendFY 2025 · to 31 Dec 20255.4%
Share count trendFY 2025 · to 27 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.9M
Free cash flowFY 2025 · to 31 Dec 2025−$9.8M

Analyst forecasts

No analyst forecasts yet.